IL-PRICEFX
14.5.2020 15:32:04 CEST | Business Wire | Press release
Pricefx , the global leader in native cloud pricing software, today introduced Lightning , the first turnkey solution to enable rapid activation of pricing excellence. Powered by Pricefx Accelerators, Lightning delivers a full suite of standard pricing analytics, management and CPQ realization tools, able to go live in six weeks or less. Customers can accelerate their Pricefx implementation with fast, easy to deploy, pre-configured pricing capabilities.
Businesses are increasingly considering pricing software as a way to navigate the current economic climate. Yet when trying to improve their enterprise pricing approach, customers can face a steep climb to reach activation.
“In my experience, it’s not uncommon for companies to struggle getting started with pricing software,” said Robert Kugel, Senior Vice President and Research Director at Ventana Research. “Starting with a blank whiteboard and getting all stakeholders to agree on the strategy, rules, fundamental approaches and a budget can derail a project before it gets off the ground. With Lightning, Pricefx is attempting to address these challenges by offering pre-configured pricing capabilities out of the box. Using a point-click-deploy approach, Pricefx Lightning is designed to significantly reduce the barriers to adopting a full scope pricing solution.”
Pricefx Lightning offers industry standard, pre-configured foundations for analytics dashboards, pre-defined yet flexible pricing strategies, and instant communication to the field. Removing the friction from implementing a full scope pricing solution, Pricefx offers a point-click-deploy approach designed to empower users who only need to add data to get started. This allows organizations to start the process from the halfway point, skipping weeks or months working through initial configurations.
Once up and running, Pricefx enables users to refine and customize focused on their specific business needs, removing costly proof of concept cycles spent on defining basic requirements. Powered by Pricefx PriceAnalyzer and Sales Insights Accelerator, Lightning provides a powerful pre-configured data analytics environment of out-of-the-box dashboards with more than a dozen optional additional configurations. To gain pricing insights, users simply load their data and start seeing new opportunities for growth and improvement.
To activate analytics-powered insights, Pricefx Lightning provides a robust price setting and management capability connected directly into the customer’s analytics, making the implementation of new intelligence seamless and instant. The analytics and management are natively integrated into the platform, which allows the strategy to be delivered to the field organization in real time. Pricefx pricing platform uses a full featured CPQ including standard workflows, in-line approvals, chat and e-signature support, removing any barriers to delivering pricing excellence.
“Lightning is a first-of-its-kind, tech-enabled fast lane for pricing excellence, designed to supercharge your implementation without breaking the bank,” said Marcin Cichon, CEO and co-founder at Pricefx. “At the outset of this initiative, our goal was to skip the POC stage and get customers working with a live product. We believe that by delivering out-of-the-gate value Pricefx can provide an informed launch point that enables businesses to focus on enhancements that create a competitive advantage and build organizational alignment with real data and results. With Lightning, we can dramatically accelerate time-to-value and have customers running live in six weeks – no one else on the market can deliver that.”
Lightning is the result of 18 months of work, with dozens of customers in more than 10 vertical industries. Its broad, versatile and flexible standard set of pre-configurations are designed to meet the analytics, management and realization needs of any organization looking to rapidly improve their entire pricing capability.
Lightning is free to activate through June 2020 with a signed subscription agreement for the three modules that power the solution – PriceAnalyzer , PriceBuilder and QuoteConfigurator . Interested customers should contact their current Pricefx representative for more information .
About Pricefx
Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, providing industry leading time to value and total cost of ownership advantages to customers. Their innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Today, Pricefx delivers Passion for Pricing to more than 100 customers in more than 37 countries worldwide. For more information, please visit www.pricefx.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200514005236/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom